Scarica l'app Stockscreener
2.82
6.62%
-0.20
Dopo l'orario di chiusura:
2.79
-0.03
-1.06%
Icecure Medical Ltd Borsa (ICCM) Ultime notizie
IceCure Medical (ICCM) grants 131K RSUs to North America VP - Stock Titan
IceCure Medical : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
IceCure Medical (NASDAQ: ICCM) director lists no shares - Stock Titan
IceCure (NASDAQ: ICCM) VP now holds 106K shares and RSUs - Stock Titan
IceCure Medical (ICCM) awards COO 141K new RSUs - Stock Titan
IceCure Medical (NASDAQ: ICCM) adds 73,890 RSUs to VP HR stake - Stock Titan
IceCure Medical (NASDAQ: ICCM) awards CFO 181K stock units at $0 - Stock Titan
ICCM Looks 85.8% Undervalued on GF Value™ - GuruFocus
IceCure Medical (ICCM) expands 2024 employee share incentive reserve - Stock Titan
Armistice Capital (ICCM) reports 300,332 IceCure Medical shares under shared control - Stock Titan
IceCure Medical (ICCM) Earnings Call zum 2. Quartal 2026: Umsatz im 1. Halbjahr steigt um 45 % - TradingKey
IceCure Medical (ICCM) details 324,802-share warrant issuance and $9.7M potential proceeds - Stock Titan
New studies highlight FDA-approved ProSense cry... - pluang.com
Two papers examine tumor freezing beyond the primary breast tumor - Stock Titan
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation - Sahm
IceCure Medical Q2 2026 Earnings Call Transcript - MarketBeat
IceCure Medical Ltd Q2 2026 Earnings Call Summary - Yahoo Finance
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year - GuruFocus
Earnings call transcript: IceCure Medical misses Q2 2026 estimates as shares fall - Investing.com
IceCure Medical Ltd. (ICCM) Q2 FY2026 earnings call transcript - Yahoo Finance
Icecure Medical Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
IceCure net loss widens to USD 8.78 million in H1 FY26; revenue rises 45% to USD 1.82 million - Bitget
IceCure Medical (Nasdaq: ICCM) lifts H1 revenue 45% but burns cash - Stock Titan
IceCure First-Half 2026 Earnings: 45% Revenue Growth Comes With Wider Losses - TradingKey
IceCure Medical (ICCM) names David Salton to board as independent director - Stock Titan
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 (PR Newswire) - Aktiellt
Earnings To Watch: Icecure Medical Ltd (ICCM) Q2 2026 -- GF Value Sees 452% Upside - GuruFocus
IceCure Medical Shareholders Approve Special Meeting Agenda on August 6, 2026 - The Globe and Mail
IceCure Medical (ICCM) holders approve agenda after adjourned meeting - Stock Titan
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment - Morningstar
IceCure Medical to Report First Half 2026 Financial and Operatin - GuruFocus
IceCure Medical Adds Adventist Health as U.S. Clinical Site for - GuruFocus
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026 - Finviz
IceCure Medical Will Discuss Six-Month Results on Aug. 12 - Stock Titan
Price to book forward of IceCure Medical Ltd. – NASDAQ:ICCM - TradingView
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense - Morningstar
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Ca - GuruFocus
IceCure Medical Kicks Off its Post-Marketing ChoICE Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site - marketscreener.com
Icecure Medical Ltd (ICCM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Icecure Medical Ltd (ICCM) Institutional Confidence - TradingKey
Icecure Medical Ltd (ICCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IceCure Medical Kicks Off Post-Marketing ChoICE Study for ProSense Cryoablation in Low-Risk Breast Cancer Treatment at First U.S. Clinical Site - marketscreener.com
Icecure Medical Ltd (ICCM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Icecure Medical Ltd (ICCM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IceCure Medical launches U.S. post-marketing st... - Pluang
IceCure Medical Kicks Off Its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site - 富途牛牛
Icecure Medical Ltd (ICCM) Cash Flow - TradingKey
IceCure study to track up to 400 patients using frozen-tumor treatment - Stock Titan
IceCure Medical Ltd. Revenue Breakdown – NASDAQ:ICCM - TradingView
Icecure Medical Ltd (ICCM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IceCure Medical (ICCM) Slumps 4.64% as Support Levels LoomPSAR Stop - dars.gov.et
ICCM|Icecure Medical Ltd|Price:3.080|Chg%:-0.150 - TradingKey
Icecure Medical Ltd|Price:3.080|Chg%:-0.150 - TradingKey
TradingKey - TradingKey
Why Has IceCure Medical's Stock Price Collapsed - Kavout | AI
IceCure Medical (ICCM) Slips 2.17% as Shares Consolidate Near Key Support LevelLong Setup Ideas - dars.gov.et
What's going on with IceCure Medical stock on Friday? - MSN
IceCure Medical Faces Sharp Decline: ICCM Drops 9.6% as Support Levels Are TestedLarge Cap Trends - dars.gov.et
Price to sales forward of IceCure Medical Ltd. – NASDAQ:ICCM - TradingView
Meir Peleg Net Worth (2026) - GuruFocus
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation - Sahm
ICCM: First FDA-cleared minimally invasive cryoablation device for breast cancer, driving global growth - TradingView
IceCure Medical (ICCM) Expands U.S. Team to Meet Growing Demand for ProSense® System - GuruFocus
IceCure Medical (ICCM) Expands Sales and Marketing Teams Nationw - GuruFocus
Enterprise value to revenue forward of IceCure Medical Ltd. – NASDAQ:ICCM - TradingView
IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer - AOL.com
IceCure Medical Ltd. emphasized that following FDA approval for breast cancer treatment, the commercial application of its Prosense™ cryoablation system is continuously expanding in Brazil. - Bitget
2.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):